Advertisement

Citations to this article

Abstract

Mice deleted for the plasminogen activator inhibitor-1 (PAI-1) gene are relatively protected from developing pulmonary fibrosis induced by bleomycin. We hypothesized that PAI-1 deficiency reduces fibrosis by promoting plasminogen activation and accelerating the clearance of fibrin matrices that accumulate within the damaged lung. In support of this hypothesis, we found that the lungs of PAI-1–/– mice accumulated less fibrin after injury than wild-type mice, due in part to enhanced fibrinolytic activity. To further substantiate the importance of fibrin removal as the mechanism by which PAI-1 deficiency limited bleomycin-induced fibrosis, bleomycin was administered to mice deficient in the gene for the Aα-chain of fibrinogen (fib). Contrary to our expectation, fib–/– mice developed pulmonary fibrosis to a degree similar to fib+/– littermate controls, which have a plasma fibrinogen level that is 70% of that of wild-type mice. Although elimination of fibrin from the lung was not in itself protective, the beneficial effect of PAI-1 deficiency was still associated with proteolytic activity of the plasminogen activation system. In particular, inhibition of plasmin activation and/or activity by tranexamic acid reversed both the accelerated fibrin clearance and the protective effect of PAI-1 deficiency. We conclude that protection from fibrosis by PAI-1 deficiency is dependent upon increased proteolytic activity of the plasminogen activation system; however, complete removal of fibrin is not sufficient to protect the lung.

Authors

Noboru Hattori ... Richard H. Simon, Angela F. Drew

×

Total citations by year in Crossref

Year: 2014 2013 2012 2011 2009 2008 2007 2006 2005 2004 2003 2002 2001 Total
Citations: 1 2 3 4 2 6 2 5 7 3 7 3 1 46
Citation information

Citations to this article in Crossref (46)

Title and authors Publication Year
New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses
N Ahluwalia, BS Shea, AM Tager
2014
Coagulation and coagulation signalling in fibrosis
PF Mercer, RC Chambers
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2013
Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)
YM Fortenberry
Expert Opinion on Therapeutic Patents 2013
Coagulation Cascade Proteinases in Lung Injury and Fibrosis
RC Chambers, CJ Scotton
Proceedings of the American Thoracic Society 2012
Role of the Lysophospholipid Mediators Lysophosphatidic Acid and Sphingosine 1-Phosphate in Lung Fibrosis
BS Shea, AM Tager
Proceedings of the American Thoracic Society 2012
Matrix Proteases in Health and Disease: BEHRENDT:MATRIX PROTEASES O-BK
F Werner, K Sachse, T Reinheckel
Matrix Proteases in Health and Disease: BEHRENDT:MATRIX PROTEASES O-BK 2012
Limiting Hepatitis C Virus Progression in Liver Transplant Recipients Using Sirolimus-Based Immunosuppression : Limiting HCV with Sirolimus
GJ McKenna, JF Trotter, E Klintmalm, N Onaca, R Ruiz, LW Jennings, M Neri, JG O’Leary, GL Davis, MF Levy, RM Goldstein, GB Klintmalm
American Journal of Transplantation 2011
Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis
I Sörensen, N Susnik, T Inhester, JL Degen, A Melk, H Haller, R Schmitt
Kidney International 2011
Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis
M Wygrecka, G Kwapiszewska, E Jablonska, S Gerlach, I Henneke, D Zakrzewicz, A Guenther, KT Preissner, P Markart
American journal of respiratory and critical care medicine 2011
Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage
B Knier, N Cordasic, B Klanke, J Heusinger-Ribeiro, C Daniel, R Veelken, A Hartner, KF Hilgers
Journal of Hypertension 2011
Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation
M Tjwa, R Moura, L Moons, S Plaisance, MD Mol, S Jansen, M Dewerchin, C Verfaillie, P Carmeliet
Journal of Cellular and Molecular Medicine 2009
Effects of Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 in Radiation-Induced Intestinal Injury
R Abderrahmani, A François, V Buard, M Benderitter, JC Sabourin, DL Crandall, F Milliat
International Journal of Radiation Oncology*Biology*Physics 2009
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy
M Gharaee-Kermani, B Hu, SH Phan, MR Gyetko
Expert Opinion on Investigational Drugs 2008
Suppressor of cytokine signaling 1 inhibits pulmonary inflammation and fibrosis
T Nakashima, A Yokoyama, Y Onari, H Shoda, Y Haruta, N Hattori, T Naka, N Kohno
Journal of Allergy and Clinical Immunology 2008
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients
K Kowal, S Żukowski, M Moniuszko, A Bodzenta-Łukaszyk
Folia Histochemica et Cytobiologica 2008
Advances in mechanisms of repair and remodelling in acute lung injury
CC Dos Santos
Intensive Care Medicine 2008
Rapamycin Inhibits PAI-1 Expression and Reduces Interstitial Fibrosis and Glomerulosclerosis in Chronic Allograft Nephropathy
P Pontrelli, M Rossini, B Infante, G Stallone, A Schena, A Loverre, M Ursi, R Verrienti, A Maiorano, G Zaza, E Ranieri, L Gesualdo, P Ditonno, C Bettocchi, FP Schena, G Grandaliano
Transplantation 2008
The Absence of uPAR Is Associated with the Progression of Dermal Fibrosis
Y Kanno, A Kaneiwa, M Minamida, M Kanno, K Tomogane, K Takeuchi, K Okada, S Ueshima, O Matsuo, H Matsuno
Journal of Investigative Dermatology 2008
Sodium in Health and Disease
P Manunta, M Sciarrone
Sodium in Health and Disease: The Example of Nonsteroidal Anti-inflammatory Agents 2007
α2-Antiplasmin is involved in the production of transforming growth factor β1and fibrosis
Y Kanno, A Kuroki, K Okada, K Tomogane, S Ueshima, O Matsuo, H Matsuno
Journal of Thrombosis and Haemostasis 2007
Idiopathic Pulmonary Fibrosis
JC Horowitz, VJ Thannickal
Treatments in Respiratory Medicine 2006
Mice lacking uteroglobin are highly susceptible to developing pulmonary fibrosis
YC Lee, Z Zhang, AB Mukherjee
FEBS Letters 2006
Idiopathic Pulmonary Fibrosis: New Concepts in Pathogenesis and Implications for Drug Therapy
JC Horowitz, VJ Thannickal
Treatments in Respiratory Medicine 2006
The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients
A Pampuch, K Kowal, A Bodzenta-Lukaszyk, AD Castelnuovo, L Chyczewski, MB Donati, L Iacoviello
Allergy 2006
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis
Y Huang, WA Border, DA Lawrence, NA Noble
Kidney International 2006

Advertisement
Advertisement